NO20033042L - Cyklodekstrin-inneholdende farmasöytisk preparat - Google Patents
Cyklodekstrin-inneholdende farmasöytisk preparatInfo
- Publication number
- NO20033042L NO20033042L NO20033042A NO20033042A NO20033042L NO 20033042 L NO20033042 L NO 20033042L NO 20033042 A NO20033042 A NO 20033042A NO 20033042 A NO20033042 A NO 20033042A NO 20033042 L NO20033042 L NO 20033042L
- Authority
- NO
- Norway
- Prior art keywords
- cyclodextrin
- pharmaceutical preparation
- containing pharmaceutical
- preparation
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
- C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D293/12—Selenazoles; Hydrogenated selenazoles
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001000247 | 2001-01-04 | ||
JP2001016022 | 2001-01-24 | ||
PCT/JP2001/011048 WO2002055076A1 (fr) | 2001-01-04 | 2001-12-17 | Preparation pharmaceutique contenant de la cyclodextrine |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20033042D0 NO20033042D0 (no) | 2003-07-02 |
NO20033042L true NO20033042L (no) | 2003-09-04 |
Family
ID=26607336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20033042A NO20033042L (no) | 2001-01-04 | 2003-07-02 | Cyklodekstrin-inneholdende farmasöytisk preparat |
Country Status (12)
Country | Link |
---|---|
US (1) | US20040053888A1 (no) |
EP (1) | EP1348432A4 (no) |
JP (1) | JPWO2002055076A1 (no) |
KR (1) | KR20030068203A (no) |
CN (1) | CN1492760A (no) |
AR (1) | AR032386A1 (no) |
BR (1) | BR0116658A (no) |
CA (1) | CA2434077A1 (no) |
MX (1) | MXPA03006071A (no) |
NO (1) | NO20033042L (no) |
RU (1) | RU2003119972A (no) |
WO (1) | WO2002055076A1 (no) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2368484A1 (en) | 1999-03-31 | 2000-10-05 | Daiichi Pharmaceutical Co., Ltd. | Substrates for thioredoxin reductase |
CN1853627B (zh) * | 2005-04-25 | 2011-08-10 | 曾慧慧 | 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途 |
JP5177429B2 (ja) | 2005-07-18 | 2013-04-03 | バイパー サイエンシズ,インコーポレイティド | 癌の治療 |
JP4886233B2 (ja) * | 2005-07-21 | 2012-02-29 | 独立行政法人物質・材料研究機構 | エブセレンの可溶化方法 |
CN100503647C (zh) * | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
EP1795183B1 (en) * | 2005-12-09 | 2009-07-15 | Teva Pharmaceutical Industries, Inc. | Aqueous dispersions and solutions of difficult to dissolve compounds and methods of their preparation |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
CN101522609A (zh) | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
US7994222B2 (en) | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
CN100486645C (zh) * | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
NZ579098A (en) * | 2007-01-16 | 2012-07-27 | Bipar Sciences Inc | Formulations for cancer treatment |
US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
AR075239A1 (es) * | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
GB201102248D0 (en) | 2011-02-09 | 2011-03-23 | Isis Innovation | Treatment of bipolar disorder |
RU2451680C1 (ru) * | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
CN107921046B (zh) | 2015-06-12 | 2022-10-14 | 格林威治大学 | 作为干扰素-γ抑制剂的三嗪衍生物 |
WO2019002889A1 (en) | 2017-06-30 | 2019-01-03 | Industrial Technology Research Institute | METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM |
WO2021054863A1 (ru) * | 2019-09-18 | 2021-03-25 | Рахимджан Ахметджанович РОЗИЕВ | Стимулятор процессов репаративной регенерации тестикулярной ткани |
WO2023240094A1 (en) * | 2022-06-06 | 2023-12-14 | Sound Pharmaceuticals Inc. | Amorphous dosage form containing ebselen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01131113A (ja) * | 1987-08-27 | 1989-05-24 | Dai Ichi Seiyaku Co Ltd | 脳障害治療剤 |
US5288734A (en) * | 1988-10-29 | 1994-02-22 | A. Nattermann & Cie Gmbh | Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same |
WO1996038175A1 (en) * | 1995-06-02 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Stabilized composition comprising an antiulcerative benzimidazole |
KR20010031520A (ko) * | 1997-11-07 | 2001-04-16 | 스즈키 다다시 | 피페라진류-시클로덱스트린 복합체 |
AU1411600A (en) * | 1998-11-30 | 2000-06-19 | Sankyo Company Limited | Immunoglobulin preparations |
-
2001
- 2001-12-17 JP JP2002555810A patent/JPWO2002055076A1/ja active Pending
- 2001-12-17 CN CNA018228720A patent/CN1492760A/zh active Pending
- 2001-12-17 MX MXPA03006071A patent/MXPA03006071A/es unknown
- 2001-12-17 WO PCT/JP2001/011048 patent/WO2002055076A1/ja not_active Application Discontinuation
- 2001-12-17 RU RU2003119972/15A patent/RU2003119972A/ru not_active Application Discontinuation
- 2001-12-17 CA CA002434077A patent/CA2434077A1/en not_active Abandoned
- 2001-12-17 EP EP01273183A patent/EP1348432A4/en not_active Withdrawn
- 2001-12-17 KR KR10-2003-7009050A patent/KR20030068203A/ko not_active Application Discontinuation
- 2001-12-17 BR BR0116658-1A patent/BR0116658A/pt not_active Application Discontinuation
- 2001-12-17 US US10/250,472 patent/US20040053888A1/en not_active Abandoned
-
2002
- 2002-01-02 AR ARP020100001A patent/AR032386A1/es unknown
-
2003
- 2003-07-02 NO NO20033042A patent/NO20033042L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20033042D0 (no) | 2003-07-02 |
CN1492760A (zh) | 2004-04-28 |
BR0116658A (pt) | 2003-12-30 |
US20040053888A1 (en) | 2004-03-18 |
AR032386A1 (es) | 2003-11-05 |
CA2434077A1 (en) | 2002-07-18 |
RU2003119972A (ru) | 2004-12-27 |
EP1348432A4 (en) | 2005-08-10 |
JPWO2002055076A1 (ja) | 2004-05-13 |
MXPA03006071A (es) | 2004-02-26 |
WO2002055076A1 (fr) | 2002-07-18 |
KR20030068203A (ko) | 2003-08-19 |
EP1348432A1 (en) | 2003-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20033143D0 (no) | Farmasoytisk preparat | |
NO20030418D0 (no) | Nytt farmasöytisk preparat | |
NO20033042L (no) | Cyklodekstrin-inneholdende farmasöytisk preparat | |
FI20011478A (fi) | Farmaseuttinen koostumus | |
NO20034026L (no) | Nytt preparat | |
NO20033556L (no) | Farmasöytiske formuleringer | |
EE200300416A (et) | Ravimvorm | |
IS7051A (is) | Lyfjasamsetningar | |
NO20035627D0 (no) | Farmasöytisk formulering | |
NO20015149L (no) | Nytt farmasöytisk preparat | |
NO20034695L (no) | Nytt preparat | |
NO20025805L (no) | Farmasöytisk preparat | |
NO20015148D0 (no) | Nytt farmasöytisk preparat | |
DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
NO20015104L (no) | Nytt farmasöytisk preparat | |
NO20015105L (no) | Nytt farmasöytisk preparat | |
DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
NO20021036D0 (no) | Farmasöytisk preparat | |
EE200300465A (et) | Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid | |
DE10107261B4 (de) | Pharmazeutische Zusammensetzung | |
NO20041236L (no) | Farmasoytisk formulering | |
FI5468U1 (fi) | Farmaseuttinen koostumus | |
SE0103116D0 (sv) | Pharmaceutical combination | |
SE0101326D0 (sv) | Pharmaceutical formulation | |
SE0103565D0 (sv) | Pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |